Cancer immunotherapy in routine cost‐effective cancer care?
Abstract Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable appro...
Saved in:
| Main Author: | Sir Marc Feldmann |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2018-10-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201809660 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prevention and treatment of neutropenia in routine clinical practice. How to improve the quality of cancer care and reduce treatment costs?
by: G. A. Gromova
Published: (2023-08-01) -
Implementing digital patient-reported outcomes in routine cancer care: barriers and facilitators
by: S.G. Aanes, et al.
Published: (2024-12-01) -
CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY
by: D. I. Vodolazhsky, et al.
Published: (2017-06-01) -
Immunotherapy in rare cancers
by: Venkata Pradeep Babu Koyyala, et al.
Published: (2020-01-01) -
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with non-small cell lung cancer in China
by: LI Yuan, GUO Lingchuan, YUAN Yong, ZHENG Qiang, JIN Yan, MING Jian
Published: (2025-02-01)